Highlight
Summary
About the Role
About You
- Accredited Bachelor’s degree in Communications, English, Journalism or related field.
- Prior experience in biopharmaceutical industry in a corporate or agency role.
- Relevant experience in corporate communications or related field.
- Outstanding interpersonal and communication skills, both written and verbal.
- Strong project management skills and a history of driving projects to completion in a fast-paced environment.
- Interest/knowledge in graphic design and content strategy.
- Ability to influence others and manage issues calmly under pressure.
Benefits
- Career advancement/development opportunities.
- Competitive compensation package including base salary and bonus.
- 401K with employer contributions.
- Generous stock options and ESPP Plan.
- 20 days of PTO to start and 18 holidays including summer and winter breaks.
- Paid paternity/maternity leave.
- In-office catered lunches and home office setup.
- Lifestyle spending stipend and commuter stipend (Boston Office).
- Regular employee social activities.
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined AML patients with high unmet need. Ziftomenib is currently enrolling patients in a Phase 2 registration-directed trial (KOMET-001) in NPM1-mutant relapsed or refractory AML. Kura is preparing to initiate multiple Phase 1 trials to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations, including NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent HNSCC. Kura intends to evaluate KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with other targeted therapies in adult patients with advanced solid tumors. For additional information, please visit Kura’s website at www.kuraoncology.com.